220119-17-5

Selamectin is formulated as a spot-on for cats and dogs to control fleas (Ctenocephalides spp.) and flea-allergy dermatitis, to prevent heartworm disease, and to control ear mites (Otodectes cynotes) in cats and dogs. It is also approved for the treatment and control of sarcoptic mange (Sarcoptes scabiei) in dogs and hookworms (Ancylostoma tubaeformis) and roundworms (Toxocara cati) in cats.

Selamectin is a semi-synthetic avermectin derivative prepared by selective hydrolysis and oximation of doramectin. Selamectin is a potent nematocide used for the treatment of endo- and exo- parasites of domestic animals, notably cats and dogs. Like the other milbemycin/avermectins, selamectin selectively binds to parasite glutamate-gated chloride ion channels and disrupts neurotransmission leading to paralysis and death of the parasite.

Selamectin is a topical parasiticide and also used as a veterinary antihelminithic agent on animals.

ChEBI: Selamectin is a milbemycin.

Topical selamectin (Revolution?—Pfizer) is indicated for flea infestations (Ctenocephalides felis), prevention of heartworm disease (Dirofilaria immitis), and for ear mites (Otodectes cynotis) in both dogs and cats. Additionally in dogs, it is indicated for sarcoptic mange (Sarcoptes scabeii), and tick infestations (Dermacentor variabilis). In cats: hookworm (Ancylostoma tubaeforme) and roundworm (Toxocara cati). The product (Revolution?) is labeled as not effective against either adult heartworms or clearing circulating microfilaria, but it possibly may have some efficacy with prolonged, continuous administration (Atkins 2007b).

Store at -20°C

Acute oral LD₅₀ for rats: >1,600 mg/kg